BridgeBio Pharma, Inc. is 10% Owner at Eidos Therapeutics, Inc. (EIDX). They have made 2 open-market trades across 1 company since 2019, most recently 2025-10-10.
2 open-market purchases totalling $55.0M since 2019, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.